pharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the company’s innovative digital collaboration with Proteus and ...

The first ever ‘digital’ pill with a built-in sensor to track compliance has been approved by the FDA, 19 months after being rejected by the agency over safety concerns. Abilify MyCite combines Otsuka ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Abilify Asimtufii? Abilify Asimtufii contains the ...

This notice was approved by the Ontario Superior Court of Justice and the Superior Court of Québec. Please read it carefully as it may affect your legal rights. TORONTO and MONTREAL, March 17, 2025 ...

Abilify is not a controlled substance. It’s an atypical antipsychotic drug. Abilify has some high risk side effects. It also carries boxed warnings, the most serious warnings from the Food and Drug ...

MONTREAL, Jan. 17, 2025 /CNW/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada has issued a Notice of Compliance for ABILIFY ASIMTUFII ® ...

Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...

Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1 Windsor, United Kingdom/Valby, Denmark, 27 March 2024 – Otsuka Pharmaceutical ...

The upcoming patent expiry of Abilify Maintena is a critical moment for Otsuka Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify ...